Recent Updates
Recently added Catalysts
AIFF Positive Sentiment Score: 70/100

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

Friday, October 11, 2024 2 min read
Key Takeaway: Firefly Neuroscience, Inc. (NASDAQ: AIFF) has announced its participation in two investor conferences in October 2024, aimed at enhancing investor engagement. The company will present its FDA-cleared Brain Network Analytics technology, which is designed to improve brain health outcomes for patients with neurological and mental disorders. This event represents an opportunity for Firefly to showcase its innovative solutions and attract potential investors and partnerships within the healthcare industry. The conferences will include a fireside chat format and are set to take place on October 17 and 30.

Market Sentiment Analysis

POSITIVE FACTORS

  • Firefly Neuroscience will participate in key investor conferences, boosting visibility.
  • The company has FDA-510(k) clearance for its innovative Brain Network Analytics technology.
  • Firefly targets pharmaceutical companies and clinicians, indicating a broad market strategy.
  • The extensive proprietary database enhances the credibility of their solutions.

Full Press Release Details

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences:
Maxim Healthcare Virtual Summit Details:
Date: October 15-17, 2024
Presentation Format: Fireside Chat with Maxim Analyst, Allen Klee
Presentation Day and Time: Thursday, October 17th at 10:00 a.m. ET
Webcast: https://investors.fireflyneuro.com/events-presentations
ThinkEquity Conference Details:
Date: October 30, 2024
Location: Mandarin Oriental Hotel, New York, NY
Presentation Day and Time: Wednesday, October 30th at 11:00 a.m. ET
Webcast: https://investors.fireflyneuro.com/events-presentations
To schedule a one-on-one investor meeting with Mr. Olsen, please contact your representatives at Maxim, ThinkEquity or email KCSA Strategic Communications at Firefly@KCSA.com.
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
KCSA Strategic Communications
Valter Pinto or Jack Perkins
KCSA Strategic Communications
Raquel Cona, Vice President

Frequently Asked Questions

What dates will Firefly participate in the Maxim Healthcare Summit?

Firefly will participate in the Maxim Healthcare Virtual Summit from October 15-17, 2024.

When is Firefly's presentation at the ThinkEquity Conference?

Firefly's presentation at the ThinkEquity Conference is on October 30, 2024, at 11:00 a.m. ET.

What technology does Firefly's BNA™ utilize?

Firefly's BNA™ technology uses AI and machine learning on a comprehensive EEG database.

How does BNA™ benefit clinicians?

BNA™ provides insights that improve diagnosis and treatment for brain health disorders.

Who can use Firefly's Brain Network Analytics?

BNA™ is targeted at pharmaceutical companies and medical practitioners for clinical use.

Tags: AIFF Viatris Investor Conferences Healthcare Firefly Neuroscience brain health investor conferences FDA clearance
Last updated: Oct 11, 2024